In addition, since mutant p53 cancers are generally of basal or triple-negative phenotype, the influence of the p53 isoforms on platinum therapies and poly(ADP-ribose) polymerase inhibitors in appropriate clinical trials would be of interest. This evidence concerns the gene TP53 and cancer.